In her Budget Speech on Monday, Finance Minister Nirmala Sitharaman announced reducing the duty to 7.5 per cent on products like primary/semi-finished products of non-alloy steel, long products of non-alloy, stainless and all
The extent of average tariff hike, based on the orders issued in 16 states by State Electricity Regulatory Commission (SERC) is at a moderate five per cent, as against the proposed revision of 5-33 per cent in petitions filed
With airlines entering into a near price-war situation once again, domestic rating agency Icra today said they should focus on securing their bottomlines by controlling costs, though it projected a better year ahead.
Balance sheets for a clutch of 22 state-owned lenders have expanded by just R3.4 lakh crore in FY16, a smaller increase compared to the rise of R4.3 lakh crore for a group of 13 private sector banks, according to data sourced
The economy is likely to show a marginal uptick in the March quarter, with gross value added (GVA) growth expected at 7.2 per cent from 7.1 per cent in the previous three-month period, domestic ratings agency Icra said today.
Absence of adequate major maintenance reserve (MMR) for road projects based on build, operate and transfer (BOT) model has exposed lenders to default risks, Icra today said in its latest study on the Indian road sector.
Home loan customers are unlikely to benefit much from the marginal cost of funds-based lending rates (MCLRs), which is expected to bring down the borrowing rates in the system, according to Icra Ratings.
ICRA estimates pan India Average Room Rates (ARRs) to remain flat for 2015-16, nevertheless occupancy improvements of six-seven per cent supports revenue per available room (RevPAR) growth of seven per cent
The sector has witnessed steady demand across therapy segments, regular new launches and price hikes taken by companies in line with DPCO guidelines Growth momentum of the domestic pharmaceutical sector is likely to sustain i
Supported by acquisitions, geographic expansion and steadily expanding product portfolio, the top-10 pharma companies from India have achieved a CAGR of 21 per cent in revenues from emerging markets over the past five years